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Abstract 
The positron emission tomography (PET) tracer 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) has 
been proposed to measure cell proliferation non-invasively in vivo. Hence, it should provide 
valuable information for response assessment to tumor therapies. To date, [18F]FLT uptake has 
found limited use as a response biomarker in clinical trials in part because a better understanding 
is needed of the determinants of [18F]FLT uptake and therapy-induced changes of its retention in 
the tumor. In this systematic review of preclinical [18F]FLT studies, comprising 174 reports, we 
identify the factors governing [18F]FLT uptake in tumors, among which thymidine kinase 1 plays a 
primary role. The majority of publications (83 %) report that decreased [18F]FLT uptake reflects 
the effects of anticancer therapies. 144 times [18F]FLT uptake was related to changes in 
proliferation as determined by ex vivo analyses. Of these approaches, 77 % describe a positive 
relation, implying a good concordance of tracer accumulation and tumor biology. These preclinical 
data indicate that [18F]FLT uptake holds promise as an imaging biomarker for response assessment 
in clinical studies. Understanding of the parameters which influence cellular [18F]FLT uptake and 
retention as well as the mechanism of changes induced by therapy is essential for successful 
implementation of this PET tracer. Hence, our systematic review provides the background for the 
use of [18F]FLT in future clinical studies. 
Key words: positron emission tomography, FLT, Oncology. 
Introduction 
Non-invasive molecular imaging with positron 
emission tomography (PET) is used in cancer research 
to identify and stage tumors and assess tumor 
response to anti-cancer treatments [1]. The most 
established tracer for PET applications is 2-[18F]-
fluoro-2-deoxy-D-glucose ([18F]FDG), whose uptake is 
regulated by glucose metabolism [2]. Due to the 
Warburg effect, uptake of [18F]FDG in tumors is 
generally high [3], making it a good candidate for 
visualization of neoplastic lesions. On the other hand, 
metabolically active organs like heart and brain, and 
glycolytic cells in inflammatory lesions accumulate 
this tracer as well. To overcome the drawbacks of 
[18F]FDG, Shields et al. proposed 3’-deoxy-3’-
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[18F]fluorothymidine ([18F]FLT) as a radiotracer for 
imaging actively proliferating cells [4]. [18F]FLT is 
taken up by cells by the same mechanisms as the 
nucleoside thymidine. This transport step is facilitated 
by nucleoside transporters, especially by the human 
equilibrative nucleoside transporter 1 (hENT1) [5]. 
Once within the cell, [18F]FLT is phosphorylated by the 
enzyme thymidine kinase 1 (TK1), which results in the 
intracellular accumulation of the tracer. Accumulation 
of [18F]FLT reflects the thymidine salvage pathway, 
specifically activity of the cytoplasmic form of TK1, 
which in turn is considered to be tightly linked to the 
S-phase of the cell proliferation cycle [6] (Fig. 1). The 
other important thymidine-to-DNA pathway is the de 
novo DNA synthesis pathway [7]. The balance of de 
novo and salvage pathways is of crucial importance for 
the accumulation rate of [18F]FLT [8,9]. 
[18F]FLT PET has previously been rarely used for 
tumor therapy follow-up in clinical trials. This is in 
part due to limited knowledge of the factors 
determining [18F]FLT uptake and therapy-induced 
changes of its retention. The Innovative Medicine 
Initiative Joint Undertaking funded project QuIC-
ConCePT aims to qualify several imaging biomarkers 
for assessing the pharmacodynamic response of 
tumors to anti-cancer drugs [10]. [18F]FLT uptake is 
one of these imaging biomarkers. To better understand 
how uptake of this radiotracer reflects cellular 
proliferation, we herein summarize the current 
literature on its preclinical and in vitro applications in 
oncology in a systematic review. We focus on the 
uptake of this tracer in untreated cells and tumors and 
evaluate the use of [18F]FLT in monitoring therapy 
response to anti-cancer treatments. A detailed 
descriptive analysis and discussion of the articles can 
be found in the Supplementary Results. In this 
manuscript we present the overall summary of the 
preclinical studies, discuss the confounding factors of 
[18F]FLT uptake and review its utility to monitor tumor 
response to therapy. These data are complemented by 
an overview of the selected study designs and 
recommendations and implications for future 
preclinical and clinical studies. 
Materials and Methods 
We performed a systematic 
search to address the question 
whether [18F]FLT accumulation 
reflects cell biology in untreated 
and treated tumors in preclinical 
model systems. Thereby, we 
adhered to the Preferred Reporting 
Items for Systematic Reviews and 
Meta-analyses (PRISMA) statement 
[11] (see PRISMA checklist in 
Supplementary Table S1). The 
search was performed in the 
bibliographic database 
Embase.com, which also includes 
the Medline database. The search 
was conducted with a combination 
of terms related to [18F]FLT and 
neoplasm (see Supplementary 
Methods) either to be included in 
the title or abstract and the study 
type filter “preclinical” was 
applied. Selection criteria were (i) 
published in English as a full paper 
in a peer-reviewed journal (no 
conference abstracts), (ii) published 
between January 1998 and January 
2016 and (iii) preclinical and / or in 
vitro data. A single person screened 
the manuscripts to confirm that 
inclusion criteria were met. Further 
details of the search strategy can be 
 
Fig. 1. Mechanisms of cellular [18F]FLT retention. Similar to thymidine in the salvage pathway, 
[18F]FLT is taken up from the extracellular milieu by specialized nucleoside transporters or via passive 
diffusion. Within the cell [18F]FLT is phosphorylated by thymidine kinase 1 (TK1), the enzyme also 
responsible for phosphorylation of thymidine. TK1 activity is dependent on adenosine triphosphate 
(ATP). The phosphorylated form of thymidine (TMP) is further phosphorylated to thymidine diphosphate 
(TDP) and thymidine triphosphate (TTP), which is subsequently incorporated into the DNA. The 
phosphorylated form of [18F]FLT cannot be incorporated into DNA but is trapped within the cell [60]. 
Techniques like PET or gamma counter measurements are capable of quantifying the rate of accumulation 
of [18F]FLT within cells. An alternative thymidine metabolism pathway is the de novo synthesis. The key 
enzyme of this pathway is thymidylate synthase (TS), which methylates deoxyuridine monophosphate 
(dUMP) to TMP. The two pathways merge at the level of TMP. Studies describing the importance of the 
different factors for [18F]FLT uptake are described in detail in the Supplementary Results. 
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found in the Supplementary Methods. 
Results  
Study identification and selection 
The search strategy identified a total of n = 388 
publications describing the use of [18F]FLT in the field 
of oncology. These were manually screened to confirm 
that the inclusion criteria were met. In addition, n = 9 
papers were found through non-automated literature 
search, that were missed by the search strategy. These 
were also included, resulting in a total of n = 174 
publications being eligible for inclusion in this review. 
Fig. 2 describes the process of study identification 
according to the PRISMA guideline. 
Design of experimental studies 
The studies varied considerably in design, which 
is described in detail in the Supplementary Results 
(chapter 3.8). Overall, colorectal cancer is the most 
commonly used cancer type addressed. [18F]FLT PET 
images were most frequently acquired 60 min after 
tracer injection for a duration of 10 min. However, the 
optimal time window might depend on the tumor 
model chosen. In contrast, therapy protocols were less 
harmonized. For instance, drug applications varied 
from daily to weekly intervals, hampering a direct 
comparison and meta-analysis of the data. These 
variances appear to recapitulate the variances in the 
clinical situation [12]. More harmonized protocols are 
needed to reliably evaluate the role of [18F]FLT PET in 
predicting therapy response in the clinic. 
[18F]FLT uptake in untreated tumors 
n = 45 publications characterize [18F]FLT uptake 
in untreated tumors. A detailed descriptive analysis of 
the confounding factors identified in these studies can 
be found in the Supplementary Results (chapter 3.2). 
In summary, it appears that uptake of the tracer is 
primarily determined by TK1 activity and the balance 
between salvage and de novo DNA synthesis 
pathways. But also other factors such as the presence 
of hENT1 or thymidine are of importance (see Table 1 
and Fig. 1). Furthermore, [18F]FLT appears to be more 
tumor specific than [18F]FDG with regards to 
inflammatory lesions, even though [18F]FLT is also 
detected in some inflammatory tissues involving 
proliferating immune cells (see also Supplementary 
Results, chapter 3.2.2). 
 
 
Fig. 2. PRISMA flow diagram. 
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Table 1. Summary of the factors important for cellular [18F]FLT 
uptake. 
Baseline [18F]FLT uptake in tumors and its change in response to therapy 
varies greatly as a result of an overall balance of some or all of the factors 
below: 
- TK1 expression levels 
- TK1 activity 
- ATP levels, as a cofactor for TK1 activity  
- TS levels and activity (de novo DNA pathway), competing with the salvage 
DNA synthesis 
- TP expression and activity, influencing endogenous tumor thymidine 
levels  
- Thymidine levels in tumor, reflecting the nucleotide turnover rates 
- Expression of nucleoside transporters, which are essential for the 
transport of [18F]FLT (notably hENT1) 
- Delivery of the tracer 
- Blood-brain barrier hampers [18F]FLT uptake in brain tumors 
- Thymidine levels in blood plasma, which are competing with  
[18F]FLT 
- Animal body temperature 
- Anesthetics used 
- Oxygen breathing 
- Tumor vascularity, and the changes thereof by antiangiogenic treatments 
 
 
Changes of [18F]FLT uptake in treated tumors 
n = 147 studies use [18F]FLT to monitor treatment 
response. Of these, next to radiotherapy, n = 21 
different chemotherapeutic agents and n = 46 targeted 
agents were employed. A comprehensive description 
and discussion of these publications is presented in the 
Supplementary Results (chapter 3.3-3.7). 
In summary, n = 122 studies describe a decline of 
[18F]FLT after tumor treatment in responsive tumor 
models (83 % of the 147 studies evaluating treatment 
response, Fig. 3A) which is in line with reduced 
proliferation of the tumor. Several of these studies 
report unchanged [18F]FLT when proliferation is not 
changed, for instance at very early time points after 
therapy initiation. Also in resistant models, [18F]FLT 
uptake is not altered upon treatment, underlining that 
changes in [18F]FLT accumulation are specific for 
changes in tumor proliferation, as demonstrated in 
n = 14 studies [13–25]. 
n = 14 of the 122 reports with reduced [18F]FLT 
accumulation after therapy, demonstrate that at the 
end of a treatment cycle, [18F]FLT levels might not be 
distinguishable from baseline, reflecting recovery of 
tumor proliferation as shown by respective 
immunohistochemistry [9,15,26–37]. Hence, for 
successful treatment monitoring, the imaging time 
point is of crucial importance. However, since therapy 
protocols differ substantially in timing (single 
administration, daily administration, therapy on two 
consecutive days, weekly therapy, etc.) no common 
conclusion can be drawn on a general time window 
that is best suitable for assessment of treatment 
response in preclinical studies. Furthermore, these 
findings also suggest that an early decline in [18F]FLT 
uptake does not rule out the possibility that at later 
time points treatment efficacy is not maintained, 
which can partly be related to a limited half-life of 
drugs within the body. Consequently, early imaging 
might help to answer the question whether the drug 
reaches the target and affects DNA synthesis 
pathways. However, it cannot predict treatment 
outcomes without respective growth or survival 
studies. 
n = 12 studies (8.2 %) employ agents targeting TS 
and describe an increased [18F]FLT uptake early after 
treatment initiation. Most of these studies report a 
transient upregulation of TK1, which explains the 
increase in tracer uptake. This transient increase in 
[18F]FLT uptake can be referred to as flare 
phenomenon and can be attributed to the cellular 
mechanism of the therapeutic agent. Nevertheless, 
reduced cellular proliferation can be observed by 
[18F]FLT PET at later time points. In the following, 
these agents are grouped together as TS inhibitors, 
comprising agents of the group of antimetabolites, but 
also kinase inhibitors [38] or combination therapies 
[39]. 
 
 
Fig. 3. Graphical demonstration of the performance of [18F]FLT after therapeutic treatment of preclinical in vivo tumor models. (A) Of the 
n = 147 therapy follow up studies included in this review, [18F]FLT is decreased in n = 122 cases and hence readily parallels therapy response. n = 12 studies employ 
agents that inhibit TS, inducing an upregulation of the thymidine salvage pathway and hence [18F]FLT uptake. Therefore, increased [18F]FLT in early time-frames after 
drug administration reflects the mechanism of action of the drug. (B) n = 57 studies employed [18F]FLT and [18F]FDG for monitoring of treatment response. In 
n = 33 of these studies [18F]FLT appears to be superior to [18F]FDG. 
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In n = 13 therapy approaches (8.8 %) [18F]FLT 
failed to predict treatment response (i.e. unchanged 
tracer uptake despite effective therapy as assessed by 
tumor growth inhibition, immunohistochemistry of 
proliferation or similar). These studies cannot be 
attributed to a specific drug class. In most cases a 
reason for the failure is hypothesized, such as 
suboptimal timing of imaging in the case of antibody 
therapy [40], or low uptake of [18F]FLT in the tumors 
[9,41,42]. The latter might be related to preferential use 
of the thymidine de novo pathway by the tumor, which 
further complicates interpretation of changes in 
[18F]FLT uptake after treatment [43]. Two studies 
describe that unchanged [18F]FLT uptake is in line with 
unaltered Ki67 staining [24,44]. Therefore, [18F]FLT 
accurately reflects the proliferative activity of the 
tumor (true negative). Other studies describe that the 
pharmacological properties of the respective drug 
(like mild upregulation of TK1 or genetic alterations of 
the tumor, like p53 knockout) might not allow [18F]FLT 
to be used for therapy follow up [45–49]. This leaves 
only one study (0.7 %) describing an inexplicable 
failure of [18F]FLT in predicting therapy response [13].  
Of note, all of the n = 15 studies employing 
radiotherapy show that [18F]FLT reliably predicts 
treatment response. For all other therapy approaches, 
failures could be noted. Consequently, [18F]FLT uptake 
appears to be an excellent imaging biomarker to 
monitor response to radiotherapy. 
Whenever studies also employed [18F]FDG PET 
to monitor therapy response, we reported this as well 
in the detailed description in the Supplementary 
Results. Of these n = 57 studies, [18F]FLT is superior to 
[18F]FDG (i.e. changes are more pronounced or occur 
at an earlier time point) in n = 33 cases (58 %), and it is 
comparable in n = 17 studies (30 %) (Fig. 3B). 
However, these two tracers provide different 
information as they measure different 
pharmacodynamic events. 
Some in vivo studies provided numeric 
quantitative imaging data, either from PET images or 
from gamma counter measurements. This allowed us 
to estimate the changes of [18F]FLT uptake relative to 
baseline or to a respective control, as presented in 
Fig. 4 (see also Supplementary Table S2). Each data 
point represents one result of a study. Most studies 
provide more than one data point since they report on 
different time points, different model systems, etc. (see 
Supplementary Table S2 for details). When respective 
data were available, standard deviations were 
displayed.  
Of the overall n = 299 data points displayed in 
Fig. 4, n = 190 are statistically significant. The other 
data points originate from resistant tumors (blue) or 
tumors that recovered (green). In other cases, [18F]FLT 
uptake might have been determined under 
circumstances that also do not result in a change of 
tracer accumulation, for instance if the therapy dose 
employed was too low or the time point was very early 
after start of treatment. Furthermore, for some data 
points, statistical information was not provided. 
43 % of the results displayed, relate the change to 
a control group, whereas the majority are comparisons 
with baseline uptake. We were not able to see any 
major differences between these analyses. In the 
clinical setting changes in tracer uptake are generally 
compared to a baseline scan before treatment 
initiation. However, under certain circumstances, 
comparison to a control group might be preferable. For 
instance, [18F]FLT uptake might be unchanged upon 
treatment, while the signal from an untreated control 
is significantly increased. This is possible with 
cytostatic treatments, which do affect tumor growth, 
whereas no change of [18F]FLT PET measurement 
before and after treatment can be noted (see e.g. [50]). 
This is supported by the observation that individual 
cell uptake of [18F]FLT is not always affected by 
cytostatic treatments [51]. 
A maximum [18F]FLT reduction of 97 % relative 
to baseline was reported [52]. No differences between 
the different therapeutic classes were noted. However, 
a definite conclusion is hampered by the great 
variability of the experimental setups and low sample 
size of some treatment groups. This impedes proper 
statistical evaluation of the data. 
We also sorted the data according to tumor type 
investigated, quantification mode employed, or day of 
image acquisition relative to treatment initiation 
(Supplementary Fig. S9). However, we were not able 
to detect any specific groups that have a very 
pronounced reduction of [18F]FLT. The only 
remarkably different group is the one comprising the 
TS inhibitors, inducing an increase in tracer uptake. 
We displayed the results in a separate graph due to the 
variances in scaling. The increase of [18F]FLT uptake in 
this group is up to a factor of five with high 
variabilities.  
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Fig. 4. Overview of the relative change of [18F]FLT after tumor therapy in preclinical in vivo models sorted according to therapy approach. 
Wherever possible, quantitative data were extracted from the publications and calculated as percent change either relative to baseline (left column) or to a respective 
control (right column). Each data point represents a single result of a study. The standard deviation could not be extracted from all publications. Rectangles represent 
results of a single analysis. Green rectangles represent data points of tumors that have regained their proliferative capacity at the end of a treatment cycle (as proven 
by immunohistochemistry). Blue rectangles represent data points of resistant tumors. Red rectangles represent results of tumors with very low baseline [18F]FLT 
uptake. Detailed results are displayed in Supplementary Table S2. 
 
Relation of [18F]FLT uptake to proliferation  
Several studies employ ex vivo tumor analyses to 
validate in vivo imaging findings. In doing so, many 
studies pursued more than one approach of ex vivo 
validation. n = 32 publications calculated correlations 
of [18F]FLT with proliferation as assessed by tumor 
growth or histological markers of proliferation, as 
summarized in Supplementary Table S3. A multitude 
of studies describe that changes in [18F]FLT are linked 
to changes in tumor volume. Of these, n = 14 reports 
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calculated a correlation. n = 102 approaches related 
[18F]FLT uptake to histological proliferation markers 
(mostly Ki67, but also PCNA or BrdU). Of these, only 
n = 21 studies did not detect any association of 
[18F]FLT accumulation and proliferation. A link of 
[18F]FLT with TK1 expression or activity was assessed 
in n = 42 studies; of these only n = 12 were not able to 
relate these two parameters. Association of [18F]FLT 
accumulation with either of the proliferation markers 
TK1 and Ki67 appears to be comparable. Overall, 20 % 
of the approaches calculated a correlation (Fig. 5). 
57 % report that changes in [18F]FLT can be attributed 
to changes in proliferation markers. However, no 
correlation was calculated, which does not necessarily 
imply that there is no correlation. In the remaining 
23 % the proliferation markers were not related to 
tracer uptake. This number reflects the multitude of 
factors that can affect uptake and retention of [18F]FLT 
(see Table 1), confounding the link between [18F]FLT 
uptake and cellular proliferation. Nevertheless, 83 % 
of the studies successfully employed [18F]FLT to 
monitor treatment response in tumors (see Fig. 3A). It 
is likely that the number of false negative studies is 
higher than reflected in this review because negative 
results are not published on a regular basis. Also from 
the experience within the QuIC-ConCePT consortium 
we know that changes in [18F]FLT uptake might be 
disconnected from the tumor response to treatment 
despite of the use of a suitable model (unpublished 
observations).  
 
 
Fig. 5. Overview of relations of [18F]FLT with parameters of cellular 
proliferation. This pie chart depicts the relations observed in the studies 
investigated in this review. Cellular proliferation comprises 
immunohistochemistry of Ki67, PCNA, BrdU and TK1, as well as TK1 activity 
or expression analyses. Supplementary Fig. S10 depicts the respective data 
sorted more specifically for TK1 and other markers of proliferation. “Relation 
observed” relates to non-quantitative observational studies. Correlations with 
correlation coefficients > 0.7 were considered strong. 
 
To assess the preferential publication of positive 
results (i.e. publication bias), statistical approaches like 
a funnel plot would be needed. However, due to 
heterogeneities in study design and the generally low 
sample sizes usually employed in preclinical studies, 
this is not feasible here. In addition, many studies are 
not fully compliant with the ARRIVE guidelines for 
reporting preclinical studies [53], so it is sometimes 
impossible to verify that valid experimental designs 
and analyses were employed. 
Discussion  
Here, we systematically review the literature of 
preclinical [18F]FLT applications in oncology. Despite 
a range of confounding factors affecting [18F]FLT 
uptake, especially TK1 expression and activity (see 
also Table 1), numerous studies demonstrate that 
[18F]FLT can be used to monitor treatment response in 
appropriate tumor models. However, when 
interpreting [18F]FLT PET findings to delineate 
proliferating tumors or assess therapy response, 
certain considerations and pre-requisites have to be 
taken into account, like the mechanism of action of the 
therapy.  
Complementary to a recently published review 
focusing on [18F]FDG and [18F]FLT PET imaging in 
preclinical studies for monitoring anti-cancer 
treatments [54], we attempted to systematically cover 
experimental applications of [18F]FLT in the field of 
oncology to answer the question whether changes in 
[18F]FLT accumulation are indeed related to tumor 
biology. 
A biomarker, such as an imaging biomarker, is “a 
physical sign or laboratory measurement that occurs 
in association with a pathological process and that has 
putative diagnostic or prognostic utility” [55]. In 
oncology the gold standard for prognostic utility is 
overall survival (or at least progression-free survival). 
This is seldom measured in preclinical studies. In 
animals usually tumor size is measured which is the 
preclinical equivalent of objective response in humans 
using response evaluation criteria in solid tumors 
(RECIST) [1]. Only rarely is objective response 
acceptable as a surrogate for overall survival. The 
ability of changes in [18F]FLT uptake as a biomarker to 
predict tumor shrinkage (which is just another 
biomarker) is of some interest. More important here, 
however, is association of [18F]FLT with underlying 
pathological processes (biological validation). Key 
questions include [56]: (i) Do drug-induced changes in 
[18F]FLT uptake faithfully reflect drug-induced 
changes in histopathological proliferation? (ii) Does 
the temporal evolution of drug-induced changes in 
[18F]FLT uptake faithfully reflect the temporal 
evolution of drug-induced changes in 
histopathological proliferation? (iii) Do increasing 
doses of drug induce graded changes in the [18F]FLT 
uptake which reflect graded changes in 
histopathological proliferation? (iv) For which drug 
classes do these relationships hold? (v) Where do these 
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correlations break down and why? (vi) Are findings 
reproducible between laboratories? Preclinical studies 
play an essential role in imaging biomarker validation, 
as it is difficult to address these questions in man, and 
the studies reviewed here help to address every single 
one of these questions.  
Following more than 15 years of research using 
[18F]FLT, recent reports note that tumor proliferation 
imaging with this tracer may not be straightforward 
[57]. From clinical experiences [18F]FLT PET is not 
always correlated with the Ki67 proliferation index, 
considered as the gold standard of proliferation, and 
even a reverse correlation is observed in some tumors. 
Therefore, in a systematic review Chalkidou et al. 
point out that apart from technical difficulties inherent 
to PET imaging, there might be biochemical reasons 
underlying tumor biology explaining the variability of 
results [58]. Moreover, results from Vanderbilt 
University show that the magnitude of [18F]FLT 
uptake should not be considered as a surrogate of 
proliferative index [8]. Zhang et al. concluded that 
“[18F]FLT PET imaging does not always ‘light up’ 
proliferating tumors” [31].  
Various factors can affect [18F]FLT uptake 
(summarized in Table 1), specifically TK1, TS and 
hENT1 expression and activity, as well as endogenous 
thymidine levels. It appears that different parameters 
play different roles in various experimental and 
therapeutic scenarios. Even though the balance of the 
thymidine de novo and salvage pathway is of crucial 
importance, there is not a single factor responsible for 
[18F]FLT uptake in general. The interplay between the 
different determinants is complex. This should be 
considered when designing and interpreting [18F]FLT 
PET studies. 
Even though [18F]FLT is not a marker of cellular 
proliferation per se, it is capable of reflecting therapy-
induced changes in cell proliferation of many tumor 
types. 83 % of the studies investigating alterations in 
[18F]FLT uptake after tumor treatment report that 
tracer accumulation is reduced, reflecting reduced 
tumor proliferation. n = 111 approaches underpin 
these findings by respective ex vivo analyses of cellular 
proliferation. The specificity of the tracer to reflect 
changes in tumor proliferation is emphasized by 
n = 14 studies showing that [18F]FLT uptake is not 
altered in resistant models. These studies imply that 
[18F]FLT PET can be employed for monitoring of 
response to anti-cancer treatments in the clinical 
situation. However, it is likely that the results 
described in this review might have literature bias as 
negative results are not always published. Potentially, 
the inclusion of conference abstracts, which are more 
likely to describe negative results, would reduce this 
bias. 
It should be kept in mind, that in general the 
study design of preclinical research is less 
standardized than clinical approaches. Parameters 
that vary include tumor type, PET imaging protocol, 
mode of PET quantification, number of subjects and 
groups, number of imaging time points, and type and 
number of interventions. The impact of these factors 
on study outcome is difficult to estimate. Therefore, 
the number of directly comparable studies is very 
limited. This hampers statistical evaluation as usually 
done in meta-analyses. Analyses such as forest plots, 
funnel plots or ROC analysis could not be pursued. 
Even though we summed up some factors, conclusions 
are rather based on a qualitative approach. This is one 
of the major limitations of this systematic review. 
Even though our review supports the 
implementation of [18F]FLT PET in clinical research, it 
needs to be determined in future larger scale clinical 
trials the extent to which our findings can be 
translated. The number of clinical studies up to now is 
limited. The QuIC-ConCePT consortium recently 
published a systematic review on [18F]FLT PET uptake 
as a measure of treatment response in cancer patients, 
following an analogous search strategy. This review 
revealed that [18F]FLT PET is indeed a good predictor 
of early response to systemic-, radio- and concurrent 
chemotherapy [59]. Furthermore, this article points 
out that the time point of imaging is of importance to 
assess treatment response accurately. This finding is 
well in line with the observations made in preclinical 
studies, as presented here. The promising nature of 
[18F]FLT PET as a tool to monitor tumor therapy 
response has also been highlighted by other clinical 
[18F]FLT reviews [12,60–62]. However, it should be 
kept in mind that [18F]FLT uptake might not be a 
reliable biomarker of proliferation in all instances, as 
pointed out in both, clinical [58,62] and preclinical [54, 
this review] systematic reviews. 
Sanghera et al. noted a vast diversity in study 
protocols [12], which is in line with our personal 
observations. Variances in uptake time, acquisition 
method, and time per bed position could influence 
quantitative measurements and analysis and thereby 
decrease comparability of results. As the optimal time 
window for imaging might depend on the model 
employed, we recommend that this time frame should 
be determined and used in preclinical studies. Future 
clinical trials should follow harmonized protocols in 
analogy to those proposed for [18F]FDG as outlined 
e.g. by the PERCIST criteria [1] or respective 
recommendations by the European Association of 
Nuclear Medicine [63]. Some further suggestions for 
harmonizing clinical [18F]FLT study protocols have 
been proposed by Peck et al. [64]. The missing 
standardization of protocols probably represents one 
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of the major challenges for reliable implementation of 
[18F]FLT PET in clinical trials. 
Only when clinical acquisition protocols have 
been standardized, the full clinical validation of 
[18F]FLT will be possible, i.e. demonstration that acute 
changes in [18F]FLT accumulation help forecast overall 
survival or progression free survival. Biological 
validation of [18F]FLT uptake is feasible via 
histological examination of tumor specimens, 
allowing relation of changes in tracer uptake to tumor 
biology. This can sometimes be done in clinical trials, 
where it is possible to recover biopsy specimens or 
tumors excised by surgery. However, this is not 
always possible in patients. To comprehensively 
understand the tumor biology underlying [18F]FLT 
uptake, preclinical studies of imaging pathology 
correlation are of great value. The aim of this review 
on preclinical [18F]FLT applications was to 
substantially improve the understanding of these 
factors. 
Whether or not preclinical studies employing 
[18F]FLT PET for monitoring cancer therapy response 
are predictive for cancer patients is the subject of 
another systematic review by the QuIC-ConCePT 
consortium, which is currently in preparation. 
Frequently, preclinical studies have employed 
subcutaneous xenografts, arising from cells cultured 
under laboratory conditions, as they are often 
reproducible, straightforward to implement, and risks 
to welfare are easily managed. However, patient 
derived xenografts [65] or genetic cancer models [66] 
appear to more closely reflect clinical cancers, and may 
be more predictive. Moreover, the use of combination 
therapies, as also employed in the clinic, might help in 
gaining more clinically relevant information. 
Based on the first promising clinical results and 
the detailed understanding of the biology underlying 
[18F]FLT accumulation in tumors, gained especially 
from preclinical studies, as described in our review, 
we are positive that [18F]FLT PET holds promise as a 
therapy response assessment tool in cancer patients. 
Moreover, it reports on completely different biology 
than does the more clinically familiar tracer [18F]FDG, 
which accumulates in glycolytic inflammatory cells 
and cancer cells. Hence, [18F]FLT accumulation and its 
changes should be further explored as an imaging 
biomarker in treatment response studies in the clinical 
situation. The following issues should be taken into 
account, when applying [18F]FLT measurements in the 
preclinical setting: 
• Low [18F]FLT uptake at baseline (SUVmax < 1; 
T/B < 1) is likely an indication that the 
investigated tumor primarily depends on de novo 
thymidine synthesis or there may be high levels 
of thymidine in the rodent strain being studied. 
Consequently, [18F]FLT is likely not to be a 
reliable tracer in these models. 
• The optimal time window for PET image 
acquisition should be carefully chosen and 
should be determined for each model in dynamic 
imaging studies. 
• All imaging parameters and protocol details 
should be thoroughly documented and included 
in future publications to allow readers to assess 
the quality of the study performed and to relate 
findings to other publications. These parameters 
include PET acquisition protocol (time of image 
acquisition, duration of scan), time point of image 
acquisition (relative to treatment initiation and / 
or tumor implantation), PET image analysis 
details (reconstruction algorithms, quantitation 
parameters), therapy protocol (drug dose, route 
of administration, application schedule), 
numbers of animals studied, and numerical 
results, including deviations. The ARRIVE 
guidelines should be followed [53] and negative 
results should be published. 
• Drugs impacting TK1 (like TS antagonists or 
antifolates) may induce an [18F]FLT flare effect. 
This might mask possible reduction of [18F]FLT 
uptake due to decreased proliferation early after 
drug administration. Up to now it is not known, 
how this flare effect might be related to treatment 
outcome. Hence, early [18F]FLT imaging of 
treatment response to drugs affecting TK1 cannot 
be recommended if the primary objective of the 
study is prediction of tumor growth arrest rather 
than target modulation. 
• Whenever possible, ex vivo correlation analyses 
with proliferation markers should be performed 
to validate in vivo PET results. 
• Tumors are heterogeneous dynamic tissues 
which might demonstrate heterogeneous 
[18F]FLT uptake and therapy response uptake 
patterns. Care should be taken to use comparable 
parameters and corresponding tumor areas in 
correlation analyses to avoid sampling errors. 
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